


Neurotransmitter Pathway Genes in Cognitive Decline During Aging: Evidence for *GNG4* and *KCNQ2* Genes

American Journal of Alzheimer's Disease & Other Dementias®
2018, Vol. 33(3) 153-165
© The Author(s) 2018
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1533317517739384
journals.sagepub.com/home/aja


Luke W. Bonham, BS¹, Daniel S. Evans, PhD², Yongmei Liu, MD, PhD³, Steven R. Cummings, MD², Kristine Yaffe, MD^{1,4,5,6}, and Jennifer S. Yokoyama, PhD¹

Abstract

Background/Rationale: Experimental studies support the role of neurotransmitter genes in dementia risk, but human studies utilizing single variants in candidate genes have had limited success. **Methods:** We used the gene-based testing program Versatile Gene-based Association Study to assess whether aggregate variation across 6 neurotransmitter pathways influences risk of cognitive decline in 8159 cognitively normal elderly (≥ 65 years old) adults from 3 community-based cohorts. **Results:** Common genetic variation in *GNG4* and *KCNQ2* was associated with cognitive decline. In human brain tissue data sets, both *GNG4* and *KCNQ2* show higher expression in hippocampus relative to other brain regions; *GNG4* expression decreases with advancing age. Both *GNG4* and *KCNQ2* show highest expression in fetal astrocytes. **Conclusion:** Genetic variation analyses and gene expression data suggest that *GNG4* and *KCNQ2* may be associated with cognitive decline in normal aging. Gene-based testing of neurotransmitter pathways may confirm and reveal novel risk genes in future studies of healthy cognitive aging.

Keywords

cognition, aging, neurotransmitter, *GNG4*, *KCNQ2*, cognitive decline

Introduction

The prevalence of dementia will rise as the world's population ages; however, the risk factors and predictors of cognitive decline in cognitively normal older individuals are not fully understood. Dementia represents the clinical manifestation of a spectrum of neurodegenerative disorders that are likely caused by multiple factors. Despite variable underlying neuropathological etiologies, many forms of dementia are characterized by progressive cognitive decline, and early changes in cognitive function are often required for diagnosis under neurodegenerative conditions such as Alzheimer's disease (AD),¹ and frontotemporal dementia.² Twin and sibling studies suggest that cognitive phenotypes such as working memory, episodic memory, and risk of dementia are heritable.³⁻⁷ Although recent research has broadened our understanding of the genetic underpinnings of cognitive decline and dementia, much remains to be understood.^{8,9}

Evidence from studies in humans and rodents suggests that neurotransmitter function declines in aging and that these changes could be associated with risk of dementia and other disorders.¹⁰⁻¹⁴ Current knowledge of genetic variation within neurotransmitter genes as risk factors for dementia is heavily derived from single-variant candidate gene studies and has often rendered mixed results. For example, common variants in *BDNF* have shown mixed associations in AD when

compared to controls, even though imaging and cognitive studies suggest that this variation influences neurodegenerative processes.^{15,16} In addition, estimated effects of single nucleotide polymorphisms (SNPs) often differ across studies. Replication of these effects is difficult, given disease heterogeneity, overestimates of risk effect in underpowered studies, and variability in genetic background across different populations. As an

¹ Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA, USA

² California Pacific Medical Center Research Institute, San Francisco, CA, USA

³ Department of Epidemiology and Prevention, Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA

⁴ Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA

⁵ Department of Veterans Affairs, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA

⁶ Department of Psychiatry, University of California, San Francisco, CA, USA

Corresponding Authors:

Jennifer S. Yokoyama, PhD, Memory and Aging Center, University of California, San Francisco, Suite 190, 675 Nelson Rising Lane, San Francisco, CA 94158, USA. Email: jennifer.yokoyama@ucsf.edu

Kristine Yaffe, MD, Departments of Psychiatry, Neurology, and Epidemiology and Biostatistics, University of California, San Francisco, San Francisco Veterans Affairs Medical Center, 4150 Clement Street, Box 181, San Francisco, CA 94121, USA. Email: kristine.yaffe@ucsf.edu

alternative to single SNP-based methods for identifying disease risk alleles, there are statistical tests that assess the combined assessment of multiple SNPs across a gene.^{17,18} Such gene-based tests are an attractive alternative to single variant tests because they reduce the burden of multiple testing, are analytically more flexible, and allow for allelic heterogeneity (i.e., when different variants within the same gene are associated with the same phenotype).^{18,19} For instance, if multiple SNPs in a single gene individually promote modest risk of cognitive decline, their effects could go unnoticed in a single-variant test due to the small and dispersed effects of each SNP.

Factors that impact global cognition may provide unique insight into the early pathological changes that underlie declines in cognitive function and mechanisms that may be helpful for combating it. Given their key roles in relaying synaptic signals throughout different networks of the brain critical for cognition, neurotransmitters are clear candidates for influencing cognitive aging. In addition to suggestive human genetic findings, research in animal models supports the role of components within neurotransmitter pathways as contributing to cognitive function in aging. For example, given the role depression may play as a risk factor for dementia,²⁰ many studies have examined candidate genes related to neurotransmitter or neuroendocrine pathways for roles in cognition and risk of neurodegenerative disorders leading to dementia such as AD. Further, the serotonin transporter length polymorphism (5-HTTLPR) has been associated with poorer memory function in older adults²¹ and with risk of dementia.²² Norepinephrine (adrenergic system) signaling is associated with better performance on memory tasks and is suggested to play a protective role against AD pathology,²³⁻²⁵ and extensive loss of norepinephrine projecting cells is often seen in AD.²³ Anticholinergic medications have been linked to cognitive decline.²⁶ One review suggests the excitatory glutamatergic system as another strong candidate system for risk of late-life depression and dementia that may relate to changes in signal transduction in older age.²⁷

Taken together, these findings suggest that multiple neurotransmitter pathways may contribute to risk for dementia, and that by investigating genes rather than single polymorphisms the authors may better understand the role these functional systems play in cognition during aging. Finally, there are many approved drugs that modulate neurotransmitter levels and are tolerated in dementia,²⁸ which makes treatment based on a gene-based analysis more tractable. For example, the drug memantine is already used to treat AD and is an *N*-Methyl-D-aspartate (glutamate) receptor antagonist and may also affect dopamine receptors.²⁹ We hypothesized that common variation in neurotransmitter genes would contribute to changes in cognitive function during aging, which could ultimately represent progression toward dementia. We used gene-based tests to assess whether genetic variation across each of the genes within specific neurotransmitter pathways influences risk of cognitive decline in healthy elderly European American participants.

Methods and Materials

Cohort Descriptions and Cognitive Measures

Three cohorts comprising a total of 8159 participants with cognitive and genetic data were used in our study. In all 3 cohorts, we required that individuals had genome-wide SNP genotypes, ≥ 2 cognitive test scores available, and were of European ancestry and unrelated based on SNP data. All participants in all studies provided written informed consent, and the institutional review boards at recruitment sites and the study-coordinating center (University of California, San Francisco) approved all aspects of this study.

Discovery Cohort—Health, Aging, and Body Composition

Our discovery cohort was the Health, Aging, and Body Composition (Health ABC) study, a prospective cohort study of 3075 community dwelling black and white men and women living in Memphis, Tennessee or Pittsburgh, Pennsylvania, and aged 70 to 79 years at recruitment in 1997. Eligible participants reported no difficulty with daily living activities, walking a quarter of a mile, or climbing 10 steps without resting at baseline. All participants were free from life-threatening cancer diagnoses and planned to live in the study area for at least 3 years. The cohort has been described in more detail in previous publications.³⁰

In the Health ABC cohort, we used 2 different measures of cognitive function: the Modified Mini-Mental State Examination (3MS), a measure of global cognition,³¹ and the Digit Symbol Substitution Test (DSST), a measure of processing speed.³² In Health ABC, the 3MS was administered in years 1, 3, 5, and 8 and the DSST was administered in years 1, 5, and 8. For phenotype generation, 3MS and DSST repeated measures from across the research period were used to calculate participant-specific slopes and intercepts for each test. As in prior work, we generated cognitive test score slopes as best linear unbiased predictions using a linear mixed model with random slopes and intercepts (Stata10, StataCorp, College Station, Texas).³³ This type of modeling enables estimation of population-level fixed effects (changes in cognitive function across the entire cohort) as well as individual-level random effects (each participant's deviation from the overall group). This approach allows each participant to have a unique intercept and trajectory (slope describing a change in cognitive function). Estimated slopes were used as a quantitative trait in association analysis with genetic variants as described below. Covariate adjustments were introduced at the genetic analysis stage, as detailed below.

Replication Cohorts—Study of Osteoporotic Fractures and Osteoporotic Fractures in Men

Our replication cohorts were the Study of Osteoporotic Fractures (SOF) and Osteoporotic Fractures in Men (MrOS) study. The SOF is a multicenter observational study of 9704 women aged 65 or older started in 1986 to study risk factors for

osteoporosis, falls, and fractures. It was expanded to include measures of successful aging and has been previously described in detail.³⁴ The MrOS study is a multicenter observational study of 5994 older men started in 2000 to study risk factors for osteoporosis, fractures, and prostate cancer susceptibility, which included multiple measures of successful aging and cognitive health. It has previously been described in detail.³⁵

In accordance with study guidelines, cognitive phenotype generation for SOF and MrOS was conducted by the San Francisco Coordinating Center (SFCC), a nonprofit academic organization that manages the clinical data for multisite studies and clinical trials. For the SOF cohort, the Mini-Mental State Examination (MMSE),³⁶ an assessment similar to the 3MS, was used as a measure of general cognitive function. The MMSE was administered in years 0, 6, 8, and 10. In the MrOS cohort, the 3MS was used as a measure of general cognitive function. The 3MS was administered in years 0, 4, and 7. For SOF and MrOS data, standardized measures of cognitive function (z scores) were separately calculated in each cohort. Participant-specific slopes were calculated by the SFCC using linear mixed effect regression models (PROC MIXED in SAS, SAS Institute, Cary, North Carolina).³⁷ In the SOF and MrOS cohorts, fixed effects of site, age, and education level were included in the cognitive score models. As in the Health ABC analyses, random effects for slope and intercept were included. Cognitive decline was scored as a dichotomous trait as the phenotype of interest, defining decline as having a slope >1 standard deviation (SD) from the group mean slope over the assessment period included in the present study.

Genotyping and Quality Control

Genotyping for Health ABC was performed on the Illumina Human1M-Duo BeadChip system by the Center for Inherited Disease Research.³³ Genotyping for SOF and MrOS was conducted on the Illumina Omni1-Quad array at the Broad Institute.³⁷ For individuals of European American genetic background based on principal components analysis (PCA), genotype imputation was performed using MACH/minimac to increase the number of SNPs covered in each cohort using CEU HapMap Phase 2 release 22 as reference.³⁸ The SNPs with a minor allele frequency ≥ 0.01 , call rate $>95\%$, and Hardy-Weinberg equilibrium $P > .0001$ were used for imputation. For imputed SNPs, we excluded markers with imputation accuracy <0.3 .

Gene Selection

Neurotransmitter genes were first identified using pathways identified by the *Kyoto Encyclopedia of Genes and Genomes* (KEGG)³⁹ and the Science Signaling Database of Cell Signaling (SSDCS). The KEGG is a database that provides information for the systematic analysis of gene functions by providing genomic and higher order functional information. The KEGG's PATHWAY database has graphical representations of cellular

processes such as metabolism and cellular signaling. The SSDCS was a graphical interface that allowed for the visualization of canonical pathways. It was archived in June 2015, but the original XML files used in this article are still available (<http://stke.sciencemag.org/about/help/cm>). Both databases adequately represent current knowledge on the pathways of interest—KEGG is still actively maintained and the SSDCS database was last updated in 2012. Genes belonging to these 6 neurotransmitter pathways were included in our analyses: adrenergic, cholinergic, dopaminergic, γ -aminobutyric acid (GABAergic), glutamatergic, and serotonergic.

Gene Expression

To assess the expression patterns of our most promising candidate genes, we analyzed gene expression levels in the Brainiac database (<http://www.brainiac.org/>). The database consists of 134 neuropathologically confirmed normal donors from the MRC Sudden Death Brain Bank in Edinburgh, United Kingdom, and the Sun Health Research Institute in Sun City West, Arizona. The cohort is composed of 99 males and 35 females with an average age of 58 (range 16-102). The average postmortem interval (PMI) was 41.7 hours. For each individual in the study, up to 10 brain regions were sampled: cerebellar cortex, frontal cortex, hippocampus, medulla, occipital cortex, putamen, substantia nigra, thalamus, temporal cortex, and intralobular white matter. RNA extraction, quality control steps, and analysis of array data are described elsewhere in detail.⁴⁰ In brief, RNA expression was assessed using the Affymetrix Exon 1.0 ST Array following manufacturers' protocols. Differences in transcript expression across the 10 brain regions were assessed using the default settings in Brainiac, which utilizes the maximum number of samples per region as possible based on data availability. To minimize the effects of outlier probes within a gene, Brainiac utilizes a Winsorized mean across the available probe sets.

To explore and describe the temporal and spatial patterns of gene expression among our most promising candidate genes, we used the Human Brain Transcriptome project (HBT; <http://hbatlas.org/pages/hbtd>). The HBT provides transcriptome data for the developing and adult human brain. The study used over 1340 tissue samples from 57 clinically unremarkable individuals with no large-scale genetic abnormalities. The cohort is composed of 31 males and 26 females ranging in age from 5.7 weeks postconception (pcw) to 82 years old. The average PMI was 12.1 hours. Tissue was taken from 6 major areas. We examined the hippocampus, amygdala, striatum, cerebellar cortex, mediodorsal nucleus of the thalamus, and neocortex. Cohort characteristics, RNA extraction, quality control steps, and analysis of array data are described in detail in Kang et al.⁴¹ The developers of the HBT project also used the Affymetrix Exon 1.0 ST Array to measure RNA expression.

Finally, cell type-specific expression data were obtained for selected genes using the Brain RNA-Seq tool (<http://www.brainrnaseq.org/>). All samples came from elective procedures and all postnatal tissue were deemed normal by both

Table 1. Primary Health ABC Cohort.

	Health ABC Full Cohort	Health ABC 3MS		Health ABC DSST	
		Slope > 0	Slope ≤ 0	Slope > 0	Slope ≤ 0
N	1598	939	658	886	708
Age, mean ± SD	73.7 ± 2.8	73.4 ± 2.8	74.2 ± 2.9	73.6 ± 2.8	73.9 ± 2.9
% Female	47.3%	48.9%	45.1%	46.4%	48.4%
Education, >12 years (%)	53.4%	60.6%	43.2%	51.7%	55.9%
3MS, mean ± SD	93.0 ± 5.7	94.4 ± 4.9	90.9 ± 6.1	92.6 ± 6.2	93.5 ± 4.9
DSST, mean ± SD	40.9 ± 12.0	43.7 ± 11.1	37.0 ± 11.9	37.4 ± 12.2	± 10.1

Abbreviations: DSST, Digit Symbol Substitution Test; 3MS, Modified Mini-Mental State Examination; N, number of participants; slope, cognitive trajectory slope (see Methods); SD, standard deviation.

electroencephalography and magnetic resonance imaging. We examined all available cell types including fetal astrocytes, mature astrocytes, neurons, oligodendrocytes, microglia/macrophages, and endothelial cells. Detailed descriptions of the samples and processing techniques used have been previously published.⁴²⁻⁴⁴

Statistical Analysis

We performed a 2-step analysis. First, univariate genetic associations with cognitive slope (Health ABC) or cognitive decline (SOF and MrOS) were determined for SNPs in candidate genes in each cohort separately. Next, we grouped SNPs within gene regions of interest as defined by genes' membership in specific neurotransmitter pathways in order to evaluate gene-level contributions to cognition. The 3 cohorts used for this study utilized 2 separate cognitive tests and were mixed with respect to sex composition and study initiation date, so they were not combined for analysis. Qualitative comparisons were made between the cohorts when possible.

Single-Variant Associations With Cognitive Measures

We implemented a regression model in R to test for genetic associations between SNPs and the cognitive phenotype of interest in each cohort. In the Health ABC study, we assessed SNP associations with slope of scores on 3MS or DSST separately using linear regression. Both analyses were adjusted for participants' baseline age, sex, education level, *APOE* ε4 carrier status, recruitment site, baseline cognitive test score, and population substructure. Population substructure was estimated using PCA, and the first 2 eigenvectors (from PCA) were included in the model as covariates. In the SOF and MrOS analyses, SNP associations were tested using the dichotomous phenotype of cognitive decline (slope < 0) on MMSE or 3MS, respectively, versus no decline (slope ≥ 0) via logistic regression, adjusting for age, education level, *APOE* ε4 genotype, and population substructure (through inclusion of the first 2 PCA-derived eigenvectors). In all analyses, we did not adjust for depression levels, as depression can be a prodromal sign of dementia.⁴⁵

Gene-Based Testing

The Versatile Gene-based Association Study (VEGAS) algorithm has been previously described.⁴⁶ Briefly, the VEGAS uses the University of California, Santa Cruz genome browser hg18 assembly to assign user supplied SNPs to genes. Gene boundaries were defined as ± 50 kb from the 5' and 3' end of the untranslated regions, and all SNPs within these boundaries that were analyzed for associations from each data set were included for analysis. The software then takes the full set of markers within a gene and accounts for confounding due to reference population linkage disequilibrium (LD) patterns and gene size. The VEGAS corrects for these confounders using simulations that utilize HapMap LD structures.⁴⁶ The VEGAS provides a gene-based test statistic as the sum of all χ^2 -converted SNP *P* values for a given gene. The software then calculates a null distribution of χ^2 statistics using Monte Carlo simulation, which is compared to the gene-based test statistic described above. The *P* value for a gene is calculated by comparing the empirical χ^2 statistic to the null distribution of χ^2 statistics. The Monte Carlo simulation technique is faster than traditional permutation techniques and yields similar results.⁴⁶ The maximum number of simulations was 1 000 000 (default setting), which means that the lowest possible *P* value is 1×10^{-6} .

Results

Cohort Composition

The final Health ABC cohort was comprised of 1598 cognitively normal older individuals who had either the 3MS or DSST available for analysis. There were 1597 individuals with a longitudinal 3MS profile and 1594 individuals with a longitudinal DSST profile. In the SOF cohort, 383 of 3508 women were labeled as showing cognitive decline over the test period. In the MrOS cohort, 384 of 3820 men were labeled as showing cognitive decline over the test period. The average age of participants in the 3 cohorts was in the early to mid-70s (Tables 1 and 2). The Health ABC cohort and MrOS cohorts were highly educated, with a majority of individuals reporting greater than 12 years of education, whereas a majority of the SOF cohort

Table 2. Replication SOF and MrOS Cohorts.

		Nondecliners	Decliners
SOF	N	3125	383
	Age, mean \pm SD	71.3 \pm 5.2	73.3 \pm 5.6
	Education, >12 yrs (%)	37.9%	32.6%
	MMSE, mean \pm SD	24.8 \pm 1.5	23.7 \pm 2.1
MrOS	N	3436	384
	Age, mean \pm SD	74.0 \pm 6.0	76.3 \pm 6.2
	Education, >12 years (%)	77.0%	73.2%
	3MS, mean \pm SD	94.5 \pm 4.1	87.9 \pm 10.4

Abbreviations: MMSE, Mini-Mental State Examination; MrOS, Osteoporotic Fractures in Men; 3MS, Modified Mini-Mental State Examination; N, Number of participants; Slope, cognitive trajectory slope (see Methods); SOF, Study of Osteoporotic Fractures; SD, standard deviation.

participants reported less than 12 years of education (Tables 1 and 2). Baseline scores on cognitive tests differed between individuals by cognitive trajectory; individuals with a negative slope in the Health ABC cohort or identified as cognitive decliners in the SOF or MrOS cohorts generally did worse compared to those with a positive slope or identified as nondecliners in the SOF or MrOS analyses (Tables 1 and 2).

Gene Pathway Identification

Using the KEGG and SSDCS databases, we identified a total of 330 genes associated with adrenergic, cholinergic, dopaminergic, GABAergic, glutamatergic, and serotonergic neurotransmitter pathways. A full list of these genes is available in Supplemental Data 1.

Gene-Based Analyses

VEGAS results were available for 315 of the 330 neurotransmitter genes identified through the KEGG and SSDCS databases due to SNP coverage and other factors (sex chromosome genes are not analyzable in version of VEGAS used). A graphical summary of the major findings and replicated genes from the Health ABC analyses as well as the SOF and MrOS cohorts is shown in Figure 1.

The Health ABC DSST cognitive trajectory analysis resulted in 20 genes that were significant at a P value <0.05 . In the Health ABC 3MS analysis, 17 genes were significant at a $P < .05$. Full results for these analyses are provided in Table 3. Four genes were significant in both of the Health ABC cognitive trajectory analyses: *AKT2*, *CHRNA4*, *CYP2D6*, and *GABRR3*.

To test for genes that specifically influence cognitive decline, we restricted our gene-based VEGAS analyses to the Health ABC SNPs with negative β coefficients in the regression model. The Health ABC DSST cognitive decline model resulted in 18 genes that were significant. In the Health ABC 3MS cognitive decline model, 15 of the genes tested were significant at a $P < .05$. Full results for these analyses are provided in Table 4. Results from the Health ABC cognitive

decline analyses were largely concordant with prior Health ABC cognitive trajectory analyses, with *AKT2*, *CHRNA4*, *CYP2D6*, and *GABRR3* replicating in the Health ABC DSST cognitive decline analysis and *CYP2D6* and *GABRR3* replicating in the Health ABC 3MS cognitive decline analysis.

We used the SOF and MrOS cohorts to replicate our findings from the Health ABC analyses. In both cohorts, 13 genes were significant. *GNG4* (G protein subunit gamma 4), found in the Health ABC 3MS cognitive trajectory and 3MS decline analyses, was replicated in the SOF cohort. *KCNQ2* (potassium voltage-gated channel subfamily Q member 2), found in the Health ABC DSST cognitive trajectory and DSST decline analyses, was replicated in the MrOS cohort. The results from our replication analyses are shown in Figure 1, and the full results for the SOF and MrOS analyses are provided in Table 5.

Gene Expression Analyses

Gene expression analyses were conducted for *GNG4* and *KCNQ2*, the 2 genes from the Health ABC analyses that were replicated in the MrOS or SOF cohorts, using information from 3 publicly available data sets of regional brain and cell type gene expression.

We next evaluated the extent to which *GNG4* and *KCNQ2* are expressed in brain regions associated with the cognitive functions measured in our study. Expression levels were analyzed in 10 adult brain regions, with increased expression found in areas often implicated in dementia such as the hippocampus, putamen, and frontal cortex when compared to white matter. For *GNG4*, the regions of highest expression were the hippocampus, putamen, and frontal cortex, and the region of lowest expression was intralobular white matter. There was a 2.4-fold difference in expression between the hippocampus and intralobular white matter ($P = 1.7 \times 10^{-41}$). For *KCNQ2*, the regions of highest expression were the hippocampus, frontal cortex, and temporal cortex, whereas the region of lowest expression was intralobular white matter. There was a 2.8-fold difference in expression between the hippocampus and intralobular white matter ($P = 3.0 \times 10^{-72}$). The high expression of *GNG4* and *KCNQ2* in highly plastic brain regions such as hippocampus and frontal cortex⁴⁷ supports the possibility that these genes may have a role in cognitive function. Plots of expression levels for *GNG4* and *KCNQ2* by neuroanatomical region are shown in Figure 2.

To explore and qualitatively assess the temporal expression patterns of *GNG4* and *KCNQ2*, we used expression data from human brain ranging from 5.7 pcw to 82 years old from HBT. We observed that across all 6 brain areas included in the data set, *GNG4* expression appeared to decrease over older adulthood, whereas *KCNQ2* expression remained relatively stable after birth. Plots of expression levels for *GNG4* and *KCNQ2* versus age are shown in Figure 3. Separate cell-specific gene expression analyses in human brain tissue suggested that both transcripts are most highly expressed in fetal astrocytes. For *GNG4*, neurons were the second highest expressing population, whereas *KCNQ2* showed second highest expression in adult




Figure 1. Results from HABC, SOF, and MrOS analyses major findings replicated between the Health ABC, DSST, HABC, 3MS, SOF, and MrOS cohorts are shown. Blue areas were significant and red areas were not significant. DSST, Digit Symbol Substitution Test; HABC, Health ABC; MrOS, Osteoporotic Fractures in Men; 3MS, Modified Mini-Mental State Examination; SOF, Study of Osteoporotic Fractures (The color version of this figure is available in the online version).

Table 3. Health ABC Cognitive Trajectory Analyses.

	Gene	CHR	BP Start	BP Stop	# SNPs	Test Statistic ^b	P Value
Health ABC DSST cognitive trajectory analysis	<i>CHRNA4</i>	20	61445108	61463139	58	170.5	4.89×10^{-3}
	<i>AKT2</i>	19	45428063	45483105	52	176.7	.011
	<i>GRIN1</i>	9	139153429	139183029	26	82.5	.011
	<i>PPP2R3A</i>	3	137167256	137349423	153	618.4	.013
	<i>GABRR3</i>	3	99188216	99236521	208	684.5	.013
	<i>GNB1</i>	1	1706588	1812355	53	170.2	.016
	<i>ADRBK1</i>	11	66790480	66810605	31	108.6	.017
	<i>KCNQ2</i>	20	61507985	61574437	90	196.1	.019
	<i>CREB3L1</i>	11	46255803	46299548	41	104.3	.020
	<i>CYP2D6</i>	22	40852444	40856827	50	177.8	.023
	<i>CHRM4</i>	11	46363215	46364683	13	44.6	.035
	<i>GRM2</i>	3	51716120	51727665	14	49.2	.035
	<i>CHRN4</i>	15	76703690	76720642	107	275.5	.035
	<i>SRC</i>	20	35406501	35467235	112	224.7	.036
	<i>FOS</i>	14	74815283	74818665	75	138.8	.040
	<i>CALML6</i>	1	1836125	1838593	30	81.7	.041
	<i>CHRNA3</i>	15	76674705	76700377	108	282.6	.041
	<i>PPP1CA</i>	11	66922227	66925952	40	108.8	.045
	<i>DRD1</i>	5	174800280	174803769	156	304.2	.046
	<i>SLC12A5</i>	20	44091244	44122196	104	212.7	.049
Health ABC 3MS cognitive trajectory analysis	<i>PLA2G3</i>	22	29860792	29866469	77	393.4	1.61×10^{-4}
	<i>TRAK2</i>	2	201950174	202024564	92	754.1	4.85×10^{-4}
	<i>PLD1</i>	3	172801311	173010967	289	1158.3	3.73×10^{-3}
	<i>HTR5A</i>	7	154493478	154508392	138	678.9	3.99×10^{-3}
	<i>GABRR3</i>	3	99188216	99236521	208	840.8	4.46×10^{-3}
	<i>GNG3</i>	11	62231708	62233246	37	167.0	.010
	<i>CHRM2</i>	7	136203938	136352311	298	772.4	.015
	<i>SLC6A4</i>	17	25549031	25586841	78	217.3	.023
	<i>GRM3</i>	7	86111165	86332128	260	676.8	.025
	<i>CHRNA4</i>	20	61445108	61463139	58	130.4	.025
	<i>CYP2D6</i>	22	40852444	40856827	50	169.0	.028
	<i>ITPR3</i>	6	33697138	33772326	239	546.4	.029
	<i>AKT2</i>	19	45428063	45483105	52	140.4	.031
	<i>GNAI2</i>	3	50248650	50271790	32	75.7	.040
	<i>GNG4</i>	1	233777607	233880677	141	286.1	.044
	<i>SLC38A3</i>	3	50217695	50233410	37	87.1	.046
	<i>ADCY9</i>	16	3952652	4106187	248	441.6	.050

Abbreviations: BP, base position; CHR, chromosome; DSST, Digit Symbol Substitution Test; Health ABC, Health, Aging, and Body Composition; 3MS, Modified Mini-Mental State Examination; SNP, single nucleotide polymorphism; VEGAS, Versatile Gene-Based Association Study.

Table 4. Health ABC Cognitive Decline Analyses.

	Gene	CHR	BP Start	BP Stop	# SNPs	Test Statistic	P Value
Health ABC DSST cognitive decline analysis	<i>FOS</i>	14	74815283	74818665	41	98.1	7.88×10^{-3}
	<i>CHRNA4</i>	20	61445108	61463139	26	73.9	8.93×10^{-3}
	<i>PPP2R3A</i>	3	137167256	137349423	75	306.0	.013
	<i>GNB1</i>	1	1706588	1812355	25	79.2	.013
	<i>KCNQ2</i>	20	61507985	61574437	46	110.7	.015
	<i>CYP2D6</i>	22	40852444	40856827	28	110.9	.016
	<i>CREB3L1</i>	11	46255803	46299548	22	58.1	.016
	<i>GRIN1</i>	9	139153429	139183029	14	43.1	.017
	<i>CALML6</i>	1	1836125	1838593	10	35.0	.019
	<i>GABRR3</i>	3	99188216	99236521	100	289.2	.022
	<i>AKT2</i>	19	45428063	45483105	27	76.7	.024
	<i>ADRBK1</i>	11	66790480	66810605	13	40.8	.024
	<i>GRM2</i>	3	51716120	51727665	7	29.1	.027
	<i>PPP1CA</i>	11	66922227	66925952	21	67.9	.029
	<i>CHRNA3</i>	15	76674705	76700377	58	157.0	.031
	<i>SLC12A5</i>	20	44091244	44122196	59	128.5	.032
	<i>CHRN4</i>	15	76703690	76720642	59	150.5	.033
	<i>CACNA1A</i>	19	13178256	13478274	161	286.5	.034
	Health ABC 3MS cognitive decline analysis	<i>PLA2G3</i>	22	29860792	29866469	43	261.7
<i>TRAK2</i>		2	201950174	202024564	54	444.6	7.58×10^{-4}
<i>TRAK2</i>		2	201950174	202024564	54	444.6	7.77×10^{-4}
<i>PLD1</i>		3	172801311	173010967	151	583.4	4.30×10^{-3}
<i>GABRR3</i>		3	99188216	99236521	99	388.5	4.48×10^{-3}
<i>HTR5A</i>		7	154493478	154508392	58	257.9	6.09×10^{-3}
<i>GNG3</i>		11	62231708	62233246	15	72.2	8.78×10^{-3}
<i>SLC6A4</i>		17	25549031	25586841	39	120.8	.013
<i>GRM3</i>		7	86111165	86332128	128	347.1	.019
<i>CYP2D6</i>		22	40852444	40856827	29	110.7	.019
<i>ADCY9</i>		16	3952652	4106187	128	262.7	.022
<i>CHRM2</i>		7	136203938	136352311	150	374.5	.022
<i>ITPR3</i>		6	33697138	33772326	118	271.6	.026
<i>GNG4</i>		1	233777607	233880677	68	139.3	.046
<i>GNAS</i>		20	56848189	56919645	72	143.2	.046

Abbreviations: BP, base position; CHR, chromosome; DSST, Digit Symbol Substitution Test; Health ABC, Health, Aging, and Body Composition; 3MS, Modified Mini-Mental State Examination; SNP, single nucleotide polymorphism; VEGAS, Versatile Gene-Based Association Study.

astrocytes and only modest expression in neurons (Supplemental Figure 1).

Discussion

Our findings implicate neurotransmitter pathway genes *GNG4* and *KCNQ2* with cognitive decline in 3 population-based cohorts of cognitively normal older adults. Both *GNG4* and *KCNQ2* were replicated in independent cohorts and showed greater expression in the hippocampi versus other neuroanatomical regions in a publicly available human post-mortem gene expression data set. Further, *GNG4* showed a decrease in expression from birth to old age in human brain tissue. Although our results were not significant after correction for multiple testing, they were replicated in separate cohorts, have regional brain expression patterns consistent with our outcome of interest, and are biologically plausible given the existing literature. Moreover, these findings represent an important

methodological step forward in the assessment of how genetic variation influences risk of cognitive decline.

GNG4 is a modulator and transducer of several transmembrane signaling systems⁴⁸ and plays a role in hemostasis and glucagon response.⁴⁹ Further, recent experimental evidence suggests that *GNG4* is down-regulated in the brain tissue of rodent models of AD⁴⁹ and an SNP near *GNG4* (rs291353) has been nominally associated with age at menopause in the Framingham Heart Study.⁵⁰ In the context of the Framingham Heart Study's findings, our finding that *GNG4* replicated in the all-female SOF cohort is particularly interesting. Though the role of estrogen on cognition and neurodegenerative disease is yet to be fully elucidated, there is evidence to support it as a modifier of cognitive decline and dementia risk.⁵¹⁻⁵⁶ Given this, it may not be coincidental that the *GNG4* association with cognitive decline was replicated in the all-female SOF cohort but was not significant in the all-male MrOS cohort. The role of *GNG4* in female-specific cognitive decline in aging remains to

Table 5. SOF and MrOS Cognitive Decline Analyses.

	Gene	CHR	BP Start	BP Stop	# SNPs	Test Statistic	P Value
SOF cognitive decline analysis	<i>GABRG1</i>	4	45732543	45820839	147	612.0	6.78×10^{-3}
	<i>GNG2</i>	14	51396799	51506268	365	819.2	7.93×10^{-3}
	<i>PPP2R5E</i>	14	62911107	63079832	172	563.6	9.43×10^{-3}
	<i>GABRA2</i>	4	45946338	46086813	146	722.7	9.88×10^{-3}
	<i>KCNJ14</i>	19	53650577	53661179	37	107.2	.012
	<i>RAF1</i>	3	12600099	12680700	116	351.2	.017
	<i>SLC6A13</i>	12	200051	242263	130	305.1	.017
	<i>GRIK5</i>	19	47194312	47261797	25	71.5	.020
	<i>HTR4</i>	5	147810787	148013934	234	623.6	.020
	<i>SLC38A2</i>	12	45038237	45052814	52	202.8	.021
	<i>KIF5C</i>	2	149349288	149591519	145	402.0	.022
	<i>GNG10</i>	9	113463681	113472347	87	208.8	.029
	<i>GNG4</i>	1	233777607	233880677	135	275.0	.040
MrOS cognitive decline analysis	<i>GRIA2</i>	4	158361185	158506676	107	553.2	5.40×10^{-4}
	<i>ADCY3</i>	2	24895541	24995559	190	891.8	2.59×10^{-3}
	<i>GNG12</i>	1	67939736	68071730	234	733.6	6.36×10^{-3}
	<i>HTR1E</i>	6	87704128	87783116	144	430.6	.010
	<i>GNAL</i>	18	11679264	11871919	245	565.4	.012
	<i>DRD4</i>	11	627304	630703	44	119.3	.018
	<i>KCNQ2</i>	20	61507985	61574437	85	173.3	.028
	<i>GRIA4</i>	11	104986009	105358029	377	794.7	.036
	<i>CALY</i>	10	134988917	135000465	54	112.0	.040
	<i>SHANK1</i>	19	55856895	55912007	63	116.7	.042
	<i>KCNN2</i>	5	113725914	113860096	242	499.1	.043
	<i>GABRG2</i>	5	161427225	161515123	129	271.9	.046
	<i>HTR3E</i>	3	185300660	185307477	63	139.4	.048

Abbreviations: CHR, chromosome; BP, base position; MrOS, Osteoporotic Fractures in Men; SNP, single nucleotide polymorphism; SOF, Study of Osteoporotic Fractures; VEGAS, Versatile Gene-Based Association Study.




Figure 2. *GNG4* and *KCNQ2* are most highly expressed in human hippocampus. Results of gene expression analyses for 10 brain regions in a cohort of cognitively normal adults are shown. The number of samples included for each brain area is shown below the region label on the x-axis.




Figure 3. *GNG4* and *KCNQ2* expression varies across the human life span. *GNG4* and *KCNQ2* expression levels over the human life span are shown. The period is a developmental staging system developed by Kang et al⁴¹ and used to categorize the human lifespan from embryonic development to late adulthood. Age is expressed in days and years from conception and plotted on a log scale for ease of viewing. Age in years was rounded to the nearest decimal point and added by the authors manually after generating the figures in HBT.

be further investigated in studies specifically designed to probe this question.

KCNQ2 is a transmembrane potassium channel gene that is part of the acetylcholinergic pathway and can harbor pathogenic mutations associated with epilepsy,⁵⁷ suggesting that *KCNQ2* may be important for restraining excessive neuronal signaling. Beyond the known association with epilepsy, there is growing evidence that *KCNQ2* is also associated with memory impairment in mice⁵⁸ and age-related memory impairment in drosophila.⁵⁹ Recent evidence shows that *KCNQ2* expression is decreased by $\alpha\beta$, one of the pathological proteins associated with AD.⁶⁰ Whether the effects of $\alpha\beta$ on *KCNQ2* expression mediate the memory impairments observed in model organisms remains unknown, but increased seizures and excitatory activity have been identified in AD mouse models⁶¹⁻⁶³ as well as human patients⁶⁴ and are linked to cognitive impairment. Under this framework, $\alpha\beta$ suppression of *KCNQ2* expression may contribute to the increased seizures, excitatory activity, and memory impairments seen in AD. Whether *KCNQ2* is related in a similar fashion to cognitive decline remains an open area of research.

Of note, both genes showed highest expression in fetal astrocytes. Although speculative, these findings could potentially suggest that genetic variation in *GNG4* and *KCNQ2* could be important during neurodevelopment. If this proves to be true, it would suggest that cognitive trajectories in aging are influenced by common variation in utero. Astrocytes are critical for synaptogenesis, and the role of these cells in adult neurologic and neuropsychiatric diseases is becoming increasingly appreciated.⁶⁵ Additional studies will be required to validate this

hypothesis and further explore the role of common genetic variation on neurodevelopmental processes and cognitive decline in aging.

We specifically tested the role of neurotransmitter pathway genes in cognitive decline because their protein products are more accessible as therapeutic targets than many other proteins implicated in cognitive decline. As candidate genes, *GNG4* and *KCNQ2* are particularly interesting given our observation that both are expressed at highest levels in human hippocampal tissue compared to 9 other functionally relevant brain regions and that *GNG4* expression decreases during aging. The hippocampus is one of the first regions of the brain to atrophy and accumulate pathologic $\alpha\beta$ during the earliest stages of AD and is a sensitive biomarker of clinical progression in mild cognitive impairment and AD.⁶⁶⁻⁶⁸ Although additional studies will be required to validate these findings, both candidate genes and their protein products represent potentially tractable drug targets. *KCNQ2* is perhaps the more tractable of the 2 genes, as there are already drugs known to alter potassium channel activity. One of these drugs, flupertine (an aminopyridine), works by opening potassium channels and has been shown to ameliorate stress-induced memory deficits in rodents.⁶⁹ Flupertine is already approved for use in many major markets as a nonopioid analgesic.^{70,71} Similarly, given our observation that *GNG4* expression decreases across the brain with advancing age and evidence from murine models of AD that *GNG4* expression is decreased in neurodegenerative disease,⁴⁹ it is plausible that drug treatments which increase *GNG4* could modify cognitive trajectory.

This study represents an important step forward in the utilization of gene-based testing to identify neurotransmitter pathway gene candidates that may predispose healthy individuals to cognitive decline, which may ultimately put them at greater risk of (or be an early indicator of) dementia. Our study benefits from its use of 3 well-established and characterized community-based cohorts. As community-based studies, Health ABC, SOF, and MrOS studies are designed to be more representative of the general population. Our findings are supported by gene expression evidence from pathologically confirmed normal individuals. However, our study cannot confirm causality or infer directionality in the relationship between *GNG4* or *KCNQ2* and cognitive decline. Further, our findings relied upon nominal *P* values and will require further testing to establish their significance. We were limited in the cognitive measures and phenotype scoring available for analyses, with 3 different neuropsychological tests (3MS, MMSE, and DSST) used to assess cognitive change/decline and thus our findings may capture alterations in different domains of cognition (eg, general function versus episodic memory). Our studies were conducted in individuals of European descent and thus may not apply to other populations. Future studies will be required to confirm these findings and establish mechanisms by which *GNG4* and *KCNQ2* may alter risk of cognitive decline in diverse populations. Assessing gene relationships with cognitive phenotypes derived from more specific (rather than global) neuropsychological measures may also provide insight into the cognitive domains that are particularly vulnerable in aging (e.g., memory and executive function).

In this study, we used gene-based testing to identify an association between *GNG4* and *KCNQ2* with cognitive decline in 3 cohorts of healthy older adults. We found evidence in pathology specimens suggesting links between these gene candidates and regions of the brain often associated with cognitive decline in aging and dementia. Our findings underscore the importance of neurotransmitter genes in the cognitive trajectory of healthy aging individuals and identify 2 promising candidate genes. Future studies in larger cohorts with more detailed cognitive characterization will be required to generalize these findings to broader populations and determine whether *GNG4* and *KCNQ2* directly alter disease risk and outcome.

Acknowledgments

The authors thank the Health, Aging, and Body Composition (Health ABC), SOF, and MrOS research participants for their long-standing dedication. The SOF is supported by the National Institutes of Health (NIH) funding. The National Institute on Aging (NIA) provides support under the following grant numbers: R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01 AG027576. The MrOS Study is supported by the NIH funding. The following institutes provided support: the NIA, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences, and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168,

U01 AR066160, and UL1 TR000128. The NIAMS provides funding for the MrOS ancillary study “GWAS in MrOS and SOF” under the grant number RC2 AR058973. The NIAMS provides funding for the MrOS ancillary study “replication of candidate gene associations and bone strength phenotype in MrOS” under the grant number R01 AR051124. The Health ABC study was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106. The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). The CIDR is fully funded through a federal contract from the NIH to The Johns Hopkins University, contract number HHSN268200782096C.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Primary support for data analyses was provided by NIA K24 AG031155 (KY), NIA K01 AG049152 (JSY), the Larry L. Hillblom Foundation 2012-A-015-FEL and 2016-A-005-SUP (JSY), an AFTD Susan Marcus Memorial Fund Clinical Research Grant (JSY), and the Tau Consortium (JSY).

Supplemental Material

Supplementary material for this article is available online.

References

1. Dubois B, Feldman H, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *Lancet Neurol*. 2014;13(6):614-629. doi:10.1016/S1474-4422(14)70090-0.
2. Rascofsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain*. 2011;134(pt 9):2456-2477. doi:10.1093/brain/awr179.
3. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. *Arch Gen Psychiatry*. 2006;63(2):168-174. doi:10.1001/archpsyc.63.2.168.
4. Po K, Leslie FVC, Gracia N, et al. Heritability in frontotemporal dementia: more missing pieces? *J Neurol*. 2014;261(11):2170-2177. doi:10.1007/s00415-014-7474-9.
5. Meeus B, Theuns J, Van Broeckhoven C. The genetics of dementia with Lewy bodies: what are we missing? *Arch Neurol*. 2012;69(9):1113-1118. doi:10.1001/archneurol.2011.3678.
6. Kremen WS, Panizzon MS, Franz CE, et al. Genetic complexity of episodic memory: a twin approach to studies of aging. *Psychol Aging*. 2014;29(2):404-417. doi:10.1037/a0035962.
7. Kremen WS, Jacobsen KC, Xian H, et al. Genetics of verbal working memory processes: a twin study of middle-aged men. *Neuropsychology*. 2007;21(5):569-580. doi:10.1037/0894-4105.21.5.569.
8. Van Cauwenbergh C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and

- perspectives. *Genet Med*. 2016;18(5):421-430. doi:10.1038/gim.2015.117.
9. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. *Nat Rev Neurosci*. 2008;9(10):768-778. doi:10.1038/nrn2494.
 10. Peters R. Ageing and the brain. *Postgrad Med J*. 2006;82(964):84-88. doi:10.1136/pgmj.2005.036665.
 11. Vanguilder HD, Yan H, Farley JA, Sonntag WE, Freeman WM. Aging alters the expression of neurotransmission-regulating proteins in the hippocampal synaptome. *J Neurochem*. 2010;113(6):1577-1588. doi:10.1111/j.1471-4159.2010.06719.x.
 12. Hascup KN, Hascup ER. Altered neurotransmission prior to cognitive decline in A β PP/PS1 mice, a model of Alzheimer's disease. *J Alzheimers Dis*. 2015;44(3):771-776. doi:10.3233/JAD-142160.
 13. Backman L, Lindenberger U, Li SC, Nyberg L. Linking cognitive aging to alterations in dopamine neurotransmitter functioning: recent data and future avenues. *Neurosci Biobehav Rev*. 2010;34(5):670-677. doi:10.1016/j.neubiorev.2009.12.008.
 14. Hodgkinson CA, Yuan Q, Xu K, et al. Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. *Alcohol Alcohol*. 2008;43(5):505-515. doi:10.1093/alcal/agn032.
 15. Honea RA, Cruchaga C, Perea RD, et al; Alzheimer's Disease Neuroimaging Initiative (ADNI). Characterizing the role of brain derived neurotrophic factor genetic variation in Alzheimer's disease neurodegeneration. *PLoS One*. 2013;8(9):e76001. doi:10.1371/journal.pone.0076001.
 16. Huang R, Huang J, Cathcart H, Smith S, Poduslo SE. Genetic variants in brain-derived neurotrophic factor associated with Alzheimer's disease. *J Med Genet*. 2007;44(2): e66. doi:10.1136/jmg.2006.044883.
 17. Cui Y, Kang G, Sun K, Qian M, Romero R, Fu W. Gene-centric genome-wide association study via entropy. *Genetics*. 2008;179(1):637-650. doi:10.1534/genetics.107.082370.
 18. Derkach A, Lawless JF, Merico D, Paterson AD, Sun L. Evaluation of gene-based association tests for analyzing rare variants using Genetic Analysis Workshop 18 data. *BMC Proc*. 2014;8(Suppl 1 Genetic Analysis Workshop 18 Vanessa Olmo):S9. doi:10.1186/1753-6561-8-S1-S9.
 19. Huang H, Chanda P, Alonso A, Bader JS, Arking DE. Gene-based tests of association. *PLoS Genet*. 2011;7(7):e1002177. doi:10.1371/journal.pgen.1002177.
 20. Byers AL, Yaffe K. Depression and risk of developing dementia. *Nat Rev Neurol*. 2011;7(6):323-331. doi:10.1038/nrneurol.2011.60.
 21. O'Hara R, Schröder CM, Mahadevan R, et al. Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol. *Mol Psychiatry*. 2007;12(6):544-555.
 22. Lorenzi C, Marcone A, Pirovano A, et al. Serotonin transporter and saitoxin genes in risk of Alzheimer's disease and frontotemporal lobar dementia: preliminary findings. *Neurol Sci*. 2010;31(6):741-749. doi:10.1007/s10072-010-0400-8.
 23. Heneka MT, Nadrigny F, Regen T, et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. *Proc Natl Acad Sci U S A*. 2010;107(13):6058-6063.
 24. Chmielewski WX, Mückschel M, Ziemssen T, Beste C. The norepinephrine system affects specific neurophysiological subprocesses in the modulation of inhibitory control by working memory demands. *Hum Brain Mapp*. 2017;38(1):68-81. doi:10.1002/hbm.23344.
 25. Murchison CF, Zhang X-Y, Zhang W-P, Ouyang M, Lee A, Thomas S. A distinct role for norepinephrine in memory retrieval. *Cell*. 2004;117(1):131-143.
 26. Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. *Clin Interv Aging*. 2009;4:225-233.
 27. Frisardi V, Panza F, Farooqui AA. Late-life depression and Alzheimer's disease: the glutamatergic system inside of this mirror relationship. *Brain Res Rev*. 2011;67(1-2):344-355.
 28. Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. *Am J Alzheimers Dis Other Dementias*. 2011;26(3):169-183. doi:10.1177/1533317511402051.
 29. Dominguez E, Chin TY, Chen CP, Wu TY. Management of moderate to severe Alzheimer's disease: focus on memantine. *Taiwan J Obstet Gynecol*. 2011;50(4):415-423.
 30. Yaffe K, Fiocco AJ, Lindquist K, et al. Predictors of maintaining cognitive function in older adults: the Health ABC study. *Neurology*. 2009;72(23):2029-2035.
 31. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. *J Clin Psychiatry*. 1987;48(8):314-318.
 32. Weschler D. *The Measurement of Adult Intelligence*. 1st ed. Baltimore, Maryland: Williams & Wilkins Co; 1939. doi:10.1037/10020-000.
 33. Tranah GJ, Nalls MA, Katzman SM, et al. Mitochondrial DNA sequence variation associated with dementia and cognitive function in the elderly. *J Alzheimers Dis*. 2012;32(2):357-372. doi:10.3233/JAD-2012-120466.
 34. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. *N Engl J Med*. 1995;332(12):767-773. doi:10.1056/NEJM199503233321202.
 35. Blank JB, Cawthon PM, Carrion-Petersen M Lou, et al. Overview of recruitment for the osteoporotic fractures in men study (MrOS). *Contemp Clin Trials*. 2005;26(5):557-568. doi:10.1016/j.cct.2005.05.005.
 36. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12(3):189-198.
 37. Yokoyama JS, Evans DS, Coppola G, Kramer JH, Tranah GJ, Yaffe K. Genetic modifiers of cognitive maintenance among older adults. *Hum Brain Mapp*. 2014;35(9):4556-4565. doi:10.1002/hbm.22494.
 38. International HapMap Consortium. The international HapMap project. *Nature*. 2003;426(6968):789-796. doi:10.1038/nature02168.

39. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. *Nucleic Acids Res.* 2016;44(D1): D457-D462. doi:10.1093/nar/gkv1070.
40. Ramasamy A, Trabzuni D, Guelfi S, et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. *Nat Neurosci.* 2014;17(10):1418-1428. doi:10.1038/nn.3801.
41. Kang HJ, Kawasawa YI, Cheng F, et al. Spatio-temporal transcriptome of the human brain. *Nature.* 2011;478(7370):483-489. doi:10.1038/nature10523.
42. Zhang Y, Sloan SA, Clarke LE, et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. *Neuron.* 2016;89(1):37-53. doi:10.1016/j.neuron.2015.11.013.
43. Bennett ML, Bennett FC, Liddel SA, et al. New tools for studying microglia in the mouse and human CNS. *Proc Natl Acad Sci U S A.* 2016;113(12): E1738-E1746.
44. Zhang Y, Chen K, Sloan SA, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J Neurosci.* 2014;34(36):11929-11947. doi:10.1523/JNEUROSCI.1860-14.2014.
45. Brommelhoff JA, Gatz M, Johansson B, McArdle JJ, Fratiglioni L, Pedersen NL. Depression as a risk factor or prodromal feature for dementia? Findings in a population-based sample of Swedish twins. *Psychol Aging.* 2009;24(2):373-384.
46. Liu JZ, McRae AF, Nyholt DR, et al. A versatile gene-based test for genome-wide association studies. *Am J Hum Genet.* 2010;87(1):139-145.
47. Lövdén M, Wenger E, Mårtensson J, Lindenberger U, Bäckman L. Structural brain plasticity in adult learning and development. *Neurosci Biobehav Rev.* 2013;37(9):2296-2310. doi:10.1016/j.neubiorev.2013.02.014.
48. Downes GB, Gautam N. The G protein subunit gene families. *Genomics.* 1999;62(3):544-552. doi:10.1006/geno.1999.5992.
49. Bouter Y, Kacprowski T, Weissmann R, et al. Deciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer's disease by deep sequencing. *Front Aging Neurosci.* 2014;6:75. doi:10.3389/fnagi.2014.00075.
50. Lunetta KL, D'Agostino RB, Karasik D, et al. Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study. *BMC Med Genet.* 2007;8(suppl 1): S13. doi:10.1186/1471-2350-8-S1-S13.
51. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. *Neurology.* 2000;54(10):1949-1954. doi:10.1212/WNL.54.10.1949.
52. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. *JAMA.* 1998;279(9):688-695.
53. Yaffe K. Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence? *Ann N Y Acad Sci.* 2001;949: 215-222.
54. Pines A. Alzheimer's disease, menopause and the impact of the estrogenic environment. *Climacteric.* 2016;19(5):430-432. doi:10.1080/13697137.2016.1201319.
55. Doty RL, Tourbier I, Ng V, et al. Influences of hormone replacement therapy on olfactory and cognitive function in postmenopausal women. *Neurobiol Aging.* 2015;36(6):2053-2059. doi:10.1016/j.neurobiolaging.2015.02.028.
56. Jamshed N, Ozair FF, Aggarwal P, Ekka M. Alzheimer disease in post-menopausal women: Intervene in the critical window period. *J Midlife Health.* 2014;5(1):38-40. doi:10.4103/0976-7800.127791.
57. Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease. *Nat Rev Neurosci.* 2000;1(1):21-30. doi:10.1038/35036198.
58. Peters HC, Hu H, Pongs O, Storm JF, Isbrandt D. Conditional transgenic suppression of M channels in mouse brain reveals functions in neuronal excitability, resonance and behavior. *Nat Neurosci.* 2005;8(1):51-60. <http://dx.doi.org/10.1038/nn1375>.
59. Cavaliere S, Malik BR, Hodge JLL. KCNQ channels regulate age-related memory impairment. *PLoS One.* 2013;8(4):e62445. doi:10.1371/journal.pone.0062445.
60. Mayordomo-Cava J, Yajeya J, Navarro-López JD, Jiménez-Díaz L. Amyloid-β(25-35) modulates the expression of GirK and KCNQ channel genes in the hippocampus. *PLoS One.* 2015;10(7):e0134385. doi:10.1371/journal.pone.0134385.
61. Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. *Arch Neurol.* 2009;66(4):435-440. doi:10.1001/archneurol.2009.15.
62. Palop JJ, Mucke L, Roberson ED. Quantifying biomarkers of cognitive dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: depletion of calcium-dependent proteins and inhibitory hippocampal remodeling. *Methods Mol Biol.* 2011;670:245-262. doi:10.1007/978-1-60761-744-0-17.
63. Palop JJ, Chin J, Roberson ED, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. *Neuron.* 2007;55(5):697-711. doi:10.1016/j.neuron.2007.07.025.
64. Vossel KA, Beagle AJ, Rabinovici GD, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. *JAMA Neurol.* 2013;70(9):1158-1166. doi:10.1001/jamaneurol.2013.136.
65. Molofsky A V., Krenick R, Ullian E, et al. Astrocytes and disease: a neurodevelopmental perspective. *Genes Dev.* 2012;26(9): 891-907. doi:10.1101/gad.188326.112.
66. Convit A, De Leon MJ, Tarshish C, et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. *Neurobiol Aging.* 1997;18(2):131-138. doi:S0197-4580(97)00001-8.
67. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. *Neurobiol Aging.* 2001;22(5):747-754. doi:10.1016/S0197-4580(01)00271-8.

68. Jack CR, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. *Neurology*. 1999;52(7):1397-1403. doi:10.1212/WNL.52.7.1397.
69. Huang P, Li C, Fu T, et al. Flupirtine attenuates chronic restraint stress-induced cognitive deficits and hippocampal apoptosis in male mice. *Behav Brain Res*. 2015;288:1-10. doi: 10.1016/j.bbr.2015.04.004.
70. Szelenyi I. Flupirtine, a re-discovered drug, revisited. *Inflamm Res*. 2013;62(3):251-258. doi:10.1007/s00011-013-0592-5.
71. Perovic S, Böhm M, Meesters E, Meinhardt A, Pergande G, Müller WE. Pharmacological intervention in age-associated brain disorders by flupirtine: Alzheimer's and prion diseases. *Mech Ageing Dev*. 1998;101(1-2):1-19. doi:10.1016/S0047-6374(97)00152-8.